Pfizer (PFE – Free Report) closed the most recent trading day at $25.21, moving -1.33% from the previous trading session. This change lagged the S&P 500’s 1.12% loss on the day. Meanwhile, the Dow experienced a drop of 0.31%, and the technology-dominated Nasdaq saw a decrease of 2.04%.
Shares of the drugmaker have depreciated by 4.45% over the course of the past month, underperforming the Medical sector’s loss of 2.99% and the S&P 500’s loss of 2.91%.
The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.67, marking a 18.29% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $13.99 billion, down 5.97% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.97 per share and a revenue of $63.2 billion, indicating changes of -4.5% and -0.67%, respectively, from the former year.
It’s also important for investors to be aware of any recent modifications to analyst estimates for Pfizer. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company’s business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.63% higher within the past month. Pfizer is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 8.6. This expresses a discount compared to the average Forward P/E of 14.23 of its industry.
It is also worth noting that PFE currently has a PEG ratio of 0.62. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company’s expected earnings growth trajectory. By the end of yesterday’s trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.37.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 48, which puts it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Financial Market Newsflash
No financial news published today. Check back later.
